Previous 10 |
TORONTO and HOUSTON, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA; TSX: MDNA), a clinical stage immuno-oncology company, today announced its financial results and operational highlights for the quarter ended Septembe...
TORONTO and HOUSTON, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (Nasdaq: MDNA) (TSX: MDNA), a clinical stage immuno-oncology company, today announced that Fahar Merchant, Ph.D., President and Chief Executive Officer of Medicenna, will prese...
-- Monotherapy and combination studies continue to demonstrate best - in - class potential of MDNA11 -- B ispecific IL-2/IL-13 Superkine demonstrates the potential to treat immunologically “cold” tumors TORONTO and HOUSTON, Oct...
-- Amongst an all-comer population, a single treatment with MDNA55 resulted in at least 100% increase in both 12 month progression free survival (PFS-12 of 27% versus 2 to 10% ) and 2-year survival (OS-24 of 20% vs 5 to10% ...
TORONTO and HOUSTON, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (NASDAQ: MDNA, TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will be presenting two abstracts at the EORTC-NCI-AACR ("ENA") Virtual Scientific P...
Following End of Phase 2 meeting with the FDA, Medicenna Therapeutics ([[MDNA]] +1.8%) has been advised to proceed with a hybrid control design for a Phase 3 trial of MDNA55 in recurrent glioblastoma (rGBM) with no mutation in 1DH1/1DH2 genes. The FDA may also consider an interim an...
- After consultation with the FDA, the company can conduct a hybrid registration trial that allows for the use of matched external controls for two-thirds of control arm - - The design sets a new precedent for GBM clinical trials, allowing robust OS analysis and significantly red...
Gainers: AcelRx Pharmaceuticals (ACRX) +17%, Cardiff Oncology (CRDF) +16%, Humanigen (HGEN) +14%, Medicenna Therapeutics (MDNA) +11%, Orgenesis (ORGS) +7%.Losers: iCAD (ICAD) -21%, Pieris Pharmaceuticals (PIRS) -19%, Legend Biot...
TORONTO and HOUSTON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (Nasdaq: MDNA) (TSX: MDNA), a clinical stage immuno-oncology company, today announced that Fahar Merchant, Ph.D., President and Chief Executive Officer of Medicenna, will pres...
News, Short Squeeze, Breakout and More Instantly...
Medicenna Therapeutics Corp. Company Name:
MDNA Stock Symbol:
NASDAQ Market:
TORONTO and HOUSTON, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a clinical-stage immunotherapy company focused on the development of engineered cytokines, announced today that the Company received ...